{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:58:56Z","timestamp":1791824336193,"version":"4.3.4"},"reference-count":175,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ctrv.2018.04.006","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T22:33:31Z","timestamp":1524609211000},"page":"82-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"special_numbering":"C","title":["BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall"],"prefix":"10.1016","volume":"66","author":[{"given":"Alessandro","family":"Leonetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Minari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Friboulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2018.04.006_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2018.04.006_b0010","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al. editors. Cancer Statistics Review, 1975-2014 \u2013 SEER Statistics. SEER Cancer Stat Rev 1975-2014 2016. <https:\/\/seer.cancer.gov\/csr\/1975_2014\/>."},{"key":"10.1016\/j.ctrv.2018.04.006_b0015","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.04.006_b0020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","volume":"150","author":"Govindan","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2018.04.006_b0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Collisson","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.04.006_b0030","doi-asserted-by":"crossref","first-page":"V1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2018.04.006_b0040","doi-asserted-by":"crossref","first-page":"24939","DOI":"10.1074\/jbc.273.38.24939","article-title":"Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf","volume":"273","author":"Papin","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2018.04.006_b0045","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1128\/MCB.26.6.2262-2272.2006","article-title":"Regulation and role of raf-1\/B-raf heterodimerization","volume":"26","author":"Rushworth","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0050","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.04.006_b0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/187152011795347469","article-title":"BRAF as a target for cancer therapy","volume":"11","author":"Dienstmann","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.ctrv.2018.04.006_b0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"J a. BRAF mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0065","doi-asserted-by":"crossref","first-page":"e47054","DOI":"10.1371\/journal.pone.0047054","article-title":"The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis","volume":"7","author":"Safaee Ardekani","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2018.04.006_b0070","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0b013e318148563d","article-title":"The prevalence and prognostic value of BRAF mutation in thyroid cancer","volume":"246","author":"Kebebew","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2018.04.006_b0075","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/bjc.2015.399","article-title":"Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer","volume":"114","author":"Loupakis","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0085","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2018.04.006_b0090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm.2166","article-title":"Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma","volume":"16","author":"Palanisamy","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/00313020801911512","article-title":"Detection of BRAF V600E mutation by pyrosequencing","volume":"40","author":"Tan","year":"2008","journal-title":"Pathology"},{"key":"10.1016\/j.ctrv.2018.04.006_b0100","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","article-title":"BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition","volume":"28","author":"Yao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2018.04.006_b0105","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","author":"Brose","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0110","first-page":"7001","article-title":"Missense mutations of the BRAF gene in human lung adenocarcinoma","volume":"62","author":"Naoki","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0115","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1101\/gad.1516407","article-title":"A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors","volume":"21","author":"Dankort","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2018.04.006_b0120","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1158\/0008-5472.CAN-06-4592","article-title":"Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models","volume":"67","author":"Ji","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0125","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non\u2013small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0130","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2018.04.006_b0135","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2018.04.006_b0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"Hammerman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.04.006_b0145","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations","volume":"29","author":"Marchetti","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/annonc\/mdt495","article-title":"Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations","volume":"25","author":"Kinno","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0155","first-page":"4619","article-title":"Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer","volume":"31","author":"Kobayashi","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2014.01.023","article-title":"BRAF-mutations in non-small cell lung cancer","volume":"84","author":"Brustugun","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0165","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-11-2109","article-title":"Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR\/KRAS and presence of PIK3CA\/AKT1 mutations","volume":"18","author":"Rekhtman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0170","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/PAS.0b013e31816597ca","article-title":"The histopathology of BRAF-V600E-mutated lung adenocarcinoma","volume":"32","author":"Yousem","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0175","doi-asserted-by":"crossref","first-page":"9375","DOI":"10.1158\/0008-5472.CAN-08-2223","article-title":"Genetic predictors of MEK dependence in non-small cell lung cancer","volume":"68","author":"Pratilas","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0180","doi-asserted-by":"crossref","first-page":"e40109","DOI":"10.1371\/journal.pone.0040109","article-title":"Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status","volume":"7","author":"An","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2018.04.006_b0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2015.11.006","article-title":"Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations","volume":"91","author":"Tissot","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0190","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cam4.1014","article-title":"Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation","volume":"6","author":"Ding","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0195","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2010.33.1280","article-title":"Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations","volume":"29","author":"Paik","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0200","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","article-title":"Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer","volume":"19","author":"Cardarella","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0205","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1183\/09031936.00018013","article-title":"EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype","volume":"43","author":"Warth","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ctrv.2018.04.006_b0210","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/cncr.29042","article-title":"Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium","volume":"121","author":"Villaruz","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0215","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1186\/s12885-015-1811-y","article-title":"Clinical detection and categorization of uncommon and concomitant mutations involving BRAF","volume":"15","author":"Zheng","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0220","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2018.04.006_b0225","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0230","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF V600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0235","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(16)00077-2","article-title":"Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0240","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jtho.2017.03.005","article-title":"Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling","volume":"12","author":"Schrock","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.04.006_b0250","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.lungcan.2014.10.002","article-title":"Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients","volume":"86","author":"Bordi","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0255","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.lungcan.2014.02.013","article-title":"Molecular profiling of small cell lung cancer in a Japanese cohort","volume":"84","author":"Wakuda","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0260","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/j.cllc.2016.11.014","article-title":"Molecular profiling and survival of completely resected primary pulmonary neuroendocrine carcinoma","volume":"18","author":"Lou","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0265","doi-asserted-by":"crossref","first-page":"11621","DOI":"10.1200\/JCO.2017.35.15_suppl.11621","article-title":"Molecular landscape of BRAF mutations in large cell neuroendocrine carcinoma of lung: an analysis of BRAF mutations and a case report of a BRAF non-V600E mutated tumor responding to targeted therapy","volume":"35","author":"Tamragouri","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0270","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network TCGA","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2018.04.006_b0275","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/JTO.0000000000000344","article-title":"Clinical characteristics and course of 63 patients with BRAF mutant lung cancers","volume":"9","author":"Litvak","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0280","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2017.02.024","article-title":"Investigation of patterns of nodal metastases in BRAF mutant lung cancer","volume":"108","author":"McEvoy","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0285","doi-asserted-by":"crossref","first-page":"9072","DOI":"10.1200\/JCO.2017.35.15_suppl.9072","article-title":"BRAF fusions in clinically advanced non-small cell lung cancer: an emerging target for anti-BRAF therapies","volume":"35","author":"Reddy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0290","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.1038\/srep09755","article-title":"Common oncogene mutations and novel SND1-BRAF transcript fusion in lung adenocarcinoma from never smokers","volume":"5","author":"Jang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2018.04.006_b0295","doi-asserted-by":"crossref","first-page":"S1804","DOI":"10.1016\/j.jtho.2017.09.455","article-title":"MA 02.06 BRAF Mutant NSCLC: correlation with PD-L1 expression, TMB, MSI and response to ICPi and anti-BRAF therapy","volume":"12","author":"Dudnik","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0300","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1200\/JCO.2016.34.15_suppl.9017","article-title":"Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1\/PD-L1 targeted therapies","volume":"34","author":"Spigel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0305","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/jso.23675","article-title":"The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer","volume":"110","author":"Lin","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0310","doi-asserted-by":"crossref","first-page":"e6552","DOI":"10.1097\/MD.0000000000006552","article-title":"A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer","volume":"96","author":"Cui","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ctrv.2018.04.006_b0315","doi-asserted-by":"crossref","first-page":"e101354","DOI":"10.1371\/journal.pone.0101354","article-title":"BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2018.04.006_b0320","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2015.4482","article-title":"Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ctrv.2018.04.006_b0325","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1245\/s10434-015-4640-y","article-title":"Prevalence and clinicopathological characteristics of BRAF mutations in chinese patients with lung adenocarcinoma","volume":"22","author":"Zheng","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0330","doi-asserted-by":"crossref","first-page":"v460","DOI":"10.1093\/annonc\/mdx380.003","article-title":"1300PD \u2013 Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: results of the network genomic medicine","volume":"28","author":"Kron","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0335","doi-asserted-by":"crossref","first-page":"12783","DOI":"10.18632\/oncotarget.3727","article-title":"Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma","volume":"6","author":"Bria","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.04.006_b0340","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-17-2289","article-title":"The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations\u2014the lung cancer mutation consortium (LCMC2)","volume":"24","author":"Aisner","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0345","doi-asserted-by":"crossref","first-page":"E2127","DOI":"10.1073\/pnas.1203530109","article-title":"Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1","volume":"109","author":"Ohashi","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ctrv.2018.04.006_b0350","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtho.2016.11.2231","article-title":"Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib","volume":"12","author":"Ho","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0355","article-title":"Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study","author":"Lin","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0360","unstructured":"Oxnard G, Thress K, Paweletz D, Stetson D, Dougherty B, Lai Z, et al. Mechanisms of acquired resistance to AZD9291 in EGFRT790 M positive lung cancer. In: IASLC 16th World Conf Lung Cancer; 2015."},{"key":"10.1016\/j.ctrv.2018.04.006_b0365","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/j.jtho.2017.07.017","article-title":"Acquired BRAF V600E mutation as resistant mechanism after treatment with third-generation EGFR tyrosine kinase inhibitor","volume":"12","author":"Bearz","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0370","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7754\/Clin.Lab.2015.150837","article-title":"Comparison of next-generation sequencing, quantitative PCR, and sanger sequencing for mutation profiling of EGFR, KRAS, PIK3CA and BRAF in clinical lung tumors","volume":"62","author":"Gao","year":"2016","journal-title":"Clin Lab"},{"key":"10.1016\/j.ctrv.2018.04.006_b0375","unstructured":"Oncomine TM Dx Target Test Part I: Sample Preparation and Quantification USER GUIDE; 2017."},{"key":"10.1016\/j.ctrv.2018.04.006_b0380","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"Capper","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0385","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389450116666150330114441","article-title":"Does immunohistochemistry represent a robust alternative technique in determining drugable predictive gene alterations in non-small cell lung cancer?","volume":"18","author":"Rossi","year":"2017","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.ctrv.2018.04.006_b0390","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/bjc.2016.106","article-title":"A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma","volume":"115","author":"Lo","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0395","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mds534","article-title":"Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients","volume":"24","author":"Ilie","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0400","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2013.06.014","article-title":"Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma","volume":"82","author":"Sasaki","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0405","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.humpath.2013.06.018","article-title":"Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas","volume":"44","author":"Routhier","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0410","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2017.04.022","article-title":"What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?","volume":"81","author":"Bernab\u00e9","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0415","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0420","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molonc.2015.12.008","article-title":"Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients","volume":"10","author":"Huang","year":"2016","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0425","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.jtho.2016.05.001","article-title":"Detection and monitoring of the BRAF mutation in circulating tumor cells and circulating tumor DNA in BRAF-mutated lung adenocarcinoma","volume":"11","author":"Guibert","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0430","doi-asserted-by":"crossref","unstructured":"Bivona TG, Raymond VM, Lanman RB, Nagy RJ, Banks KC, Chae YK, et al. Spectrum of 1,014 Somatic BRAF Alterations Detected in Cell-Free DNA of Patients with Advanced Non-Small Cell Lung Cancer. In: IASLC 18th World Conf Lung Cancer; 2017.","DOI":"10.1016\/j.jtho.2017.09.397"},{"key":"10.1016\/j.ctrv.2018.04.006_b0435","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1158\/1535-7163.MCT-15-0712","article-title":"BRAF mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system","volume":"15","author":"Janku","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2018.04.006_b0440","doi-asserted-by":"crossref","first-page":"49773","DOI":"10.18632\/oncotarget.17937","article-title":"The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.04.006_b0445","doi-asserted-by":"crossref","first-page":"S1940","DOI":"10.1016\/j.jtho.2017.09.776","article-title":"P1.02-043 A comparison of consistency of detecting BRAF gene mutations in peripheral blood and tumor tissue of non-small-cell lung cancer patients","volume":"12","author":"Fang","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0450","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1078-0432.CCR-06-2120","article-title":"Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy","volume":"13","author":"Shinozaki","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0455","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CMR.0000000000000187","article-title":"BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors","volume":"25","author":"Gonzalez-Cao","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0460","first-page":"309","article-title":"CfDNA analysis from blood in melanoma","volume":"3","author":"Molina-Vila","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0465","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","article-title":"Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials","volume":"22","author":"Santiago-Walker","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0470","doi-asserted-by":"crossref","first-page":"11198","DOI":"10.1038\/srep11198","article-title":"Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations","volume":"5","author":"Chang-Hao Tsao","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2018.04.006_b0475","unstructured":"Press Announcements \u2013 FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer 2016. <https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm504488.htm> (accessed December 20, 2017)."},{"key":"10.1016\/j.ctrv.2018.04.006_b0480","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12967-016-0852-6","article-title":"Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors","volume":"14","author":"Schreuer","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0485","doi-asserted-by":"crossref","unstructured":"Mezquita L, Jovelet C, Ngocamus M, Auclin E, Remon J, Green E, et al. MA 11.01 \u2013 Liquid Biopsies for Monitoring BRAF Mutation (V600E) in Advanced BRAF (V600E) Non-Small Cell Lung Cancer (NSCLC). In: IASLC 18th World Conf Lung Cancer 2017.","DOI":"10.1016\/j.jtho.2017.09.542"},{"key":"10.1016\/j.ctrv.2018.04.006_b0490","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0495","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2018.04.006_b0500","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071527","article-title":"Role played by signalling pathways in overcoming BRAF inhibitor resistance in melanoma","volume":"18","author":"Chan","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2018.04.006_b0505","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0510","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccr.2010.02.029","article-title":"The Raf inhibitor paradox: unexpected consequences of targeted drugs","volume":"17","author":"Cox","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2018.04.006_b0515","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0520","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2018.04.006_b0525","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0530","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer","volume":"33","author":"Corcoran","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctrv.2018.04.006_b0535","unstructured":"ESMO News. ESMO 2016: Triple Combination of Dabrafenib, Trametinib, and Panitumumab Improves Efficacy in BRAF Mutation Positive mCRC. ESMO Annu Meet; 2016."},{"key":"10.1016\/j.ctrv.2018.04.006_b0540","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.6023","article-title":"Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","author":"Subbiah","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0545","doi-asserted-by":"crossref","first-page":"E748","DOI":"10.1073\/pnas.1320956111","article-title":"Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer","volume":"111","author":"Lin","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ctrv.2018.04.006_b0550","doi-asserted-by":"crossref","first-page":"201610456","DOI":"10.1073\/pnas.1610456113","article-title":"Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer","volume":"113","author":"Okimoto","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2018.04.006_b0555","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.04.006_b0560","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.04.006_b0565","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/0008-5472.CAN-11-3649","article-title":"MEK1\/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E","volume":"72","author":"Trejo","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118210","article-title":"Trametinib with or without Vemurafenib in braf mutated non-small cell lung cancer","volume":"10","author":"Joshi","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2018.04.006_b0575","doi-asserted-by":"crossref","first-page":"60094","DOI":"10.18632\/oncotarget.11635","article-title":"Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib","volume":"8","author":"Noeparast","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.04.006_b0580","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0585","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0590","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/JTO.0b013e3182629903","article-title":"A Patient with BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib","volume":"7","author":"Gautschi","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0595","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1200\/JCO.2012.47.6143","article-title":"Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma","volume":"31","author":"Peters","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0600","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0605","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/JTO.0000000000000625","article-title":"Targeted therapy for patients with BRAF-mutant lung cancer results from the European EURAF cohort","volume":"10","author":"Gautschi","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0610","doi-asserted-by":"crossref","first-page":"S1182","DOI":"10.1016\/j.jtho.2016.11.1664","article-title":"P3.02a-034 Vemurafenib in patients with non-small cell lung cancer (NSCLC) harboring BRAF mutation. Preliminary results of the Acs\u00e9 trial","volume":"12","author":"Mazieres","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0615","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.lungcan.2013.08.012","article-title":"Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib","volume":"82","author":"Gautschi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0620","first-page":"3294","article-title":"BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib","volume":"8","author":"El Karak","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0625","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1200\/JCO.2017.35.15_suppl.9074","article-title":"Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation","volume":"35","author":"Subbiah","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0630","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.lungcan.2014.05.009","article-title":"BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib","volume":"85","author":"Robinson","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0635","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/j.jtho.2016.11.272","article-title":"OA08.07 BRAF-V600E Advanced lung adenocarcinoma with leptomeningeal (LM) disease treated with vemurafenib","volume":"12","author":"Fernandes","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0640","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2018.04.006_b0645","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.lungcan.2014.11.008","article-title":"Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma","volume":"87","author":"Schmid","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0650","doi-asserted-by":"crossref","first-page":"9075","DOI":"10.1200\/JCO.2017.35.15_suppl.9075","article-title":"Updated survival of patients (pts) with previously treated BRAF V600E\u2013mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study","volume":"35","author":"Planchard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0655","unstructured":"Approved Drugs \u2013 FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation 2017. <https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm564331.htm> (accessed November 10, 2017)."},{"key":"10.1016\/j.ctrv.2018.04.006_b0660","unstructured":"Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation 2017. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/002643\/WC500222159.pdf> (accessed November 23, 2017)."},{"key":"10.1016\/j.ctrv.2018.04.006_b0670","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0675","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12885-016-2463-2","article-title":"Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report","volume":"16","author":"Casadei Gardini","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0680","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/CAD.0000000000000277","article-title":"A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation","volume":"26","author":"Sereno","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2018.04.006_b0685","doi-asserted-by":"crossref","first-page":"136ra70","DOI":"10.1126\/scitranslmed.3003513","article-title":"Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib","volume":"4","author":"Sen","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0690","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1078-0432.CCR-11-0997","article-title":"BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance","volume":"18","author":"Alcal\u00e1","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0695","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0700","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/pcmr.12171","article-title":"Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain","volume":"27","author":"Wagenaar","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0705","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/pcmr.12347","article-title":"Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib","volume":"28","author":"Hoogstraat","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0710","first-page":"1","article-title":"Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK\/PI3K inhibition or MEK\/CDK4\/6 inhibition","author":"Kim","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2018.04.006_b0715","first-page":"1","article-title":"BRAF fusion as a novel mechanism of acquired resistance to Vemurafenib in BRAF V600E mutant melanoma","author":"Kulkarni","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0720","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2018.04.006_b0725","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00018-011-0878-0","article-title":"Genetic alterations of PTEN in human melanoma","volume":"69","author":"Aguissa-Tour\u00e9","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ctrv.2018.04.006_b0730","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030585","article-title":"Strategies for overcoming resistance in tumours harboring BRAF mutations","volume":"18","author":"Obaid","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2018.04.006_b0735","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/JTO.0b013e31828bb1b3","article-title":"Molecular characterization of acquired resistance to the BRAF inhibitor Dabrafenib in a patient with BRAF-mutant non\u2013small-cell lung cancer","volume":"8","author":"Rudin","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0740","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2018.04.006_b0745","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2018.04.006_b0750","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","article-title":"Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next?","volume":"62","author":"Welsh","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0755","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.04.006_b0760","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS\u2013ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2018.04.006_b0765","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccell.2014.11.006","article-title":"Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma","volume":"27","author":"Girotti","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2018.04.006_b0770","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14982","article-title":"RAF inhibitors that evade paradoxical MAPK pathway activation","volume":"526","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.04.006_b0775","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrc.2017.79","article-title":"New perspectives for targeting RAF kinase in human cancer","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0780","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1021\/jm400778d","article-title":"Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives","volume":"56","author":"Okaniwa","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2018.04.006_b0785","first-page":"774","article-title":"A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas","volume":"19","author":"Sun","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0790","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ccell.2015.08.002","article-title":"Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers","volume":"28","author":"Bin","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2018.04.006_b0795","unstructured":"US National Library of Medicine. ClinicalTrials.gov n.d. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02437227>."},{"key":"10.1016\/j.ctrv.2018.04.006_b0800","unstructured":"US National Library of Medicine. ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02974725."},{"key":"10.1016\/j.ctrv.2018.04.006_b0805","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1476-4598-13-194","article-title":"Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma","volume":"13","author":"Wong","year":"2014","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0810","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.trecan.2015.10.001","article-title":"Targeting RAS-mutant cancers: is ERK the key?","volume":"1","author":"Ryan","year":"2015","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctrv.2018.04.006_b0815","unstructured":"US National Library of Medicine. ClinicalTrials.gov n.d. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02313012>."},{"key":"10.1016\/j.ctrv.2018.04.006_b0820","unstructured":"US National Library of Medicine. ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01781429."},{"key":"10.1016\/j.ctrv.2018.04.006_b0825","unstructured":"US National Library of Medicine. ClinicalTrials.gov n.d. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01875705>."},{"key":"10.1016\/j.ctrv.2018.04.006_b0830","unstructured":"US National Library of Medicine. ClinicalTrials.gov n.d. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01358331>."},{"key":"10.1016\/j.ctrv.2018.04.006_b0845","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0850","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0855","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0860","doi-asserted-by":"crossref","first-page":"e1048929","DOI":"10.1080\/23723556.2015.1048929","article-title":"Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma","volume":"3","author":"Hellmann","year":"2016","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0865","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMe1413061","article-title":"Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma","volume":"371","author":"Boussiotis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.006_b0870","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ctrv.2018.04.006_b0875","unstructured":"US National Library of Medicine. ClinicalTrials.gov n.d. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02130466>."},{"key":"10.1016\/j.ctrv.2018.04.006_b0880","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b0885","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.006_b9005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.03.026","article-title":"An acquired NRAS Q61K mutation in BRAF V600E-mutant lung adenocarcinoma resistant to dabrafenib plus trametinib","author":"Abravanel","year":"2018","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T02:32:28Z","timestamp":1604197948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737218300501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":175,"alternative-id":["S0305737218300501"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.04.006","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}